Melanoma has one of the highest somatic mutational burdens among solid malignancies. Although the rapid progress in genomic research has contributed immensely to our understanding of the pathogenesis of melanoma, the clinical significance of the vast array of genomic alterations discovered by next-generation sequencing is far from being fully characterized. Most mutations prevalent in melanoma are simply neutral "passengers," which accompany functionally significant "drivers" under transforming conditions. The delineation of driver mutations from passenger mutations is critical to the development of targeted therapies. Novel advances in genomic data analysis have aided in distinguishing true driver mutations involved in tumor progression. Here, the authors review the current literature on important somatic driver mutations in melanoma, along with the implications for treatment. Cancer
INTRODUCTION
In 2016, there will be an estimated 76,380 new diagnoses of cutaneous melanoma in the United States and 10,130 deaths related to melanoma. 1 Elucidation of important mutations in melanoma has led to the development of therapies that have improved survival. 2, 3 Hence, a comprehensive understanding of the mutational landscape of melanoma has been, and will continue to be, essential in developing novel treatments. The identification of critical perturbations within a background of random aberrations in the cancer genome remains a major challenge. Large-scale initiatives have revealed that somatic cancer genomes characteristically have a staggering number of mutations within individual tumors. However, only a few mutations, referred to as "driver" mutations, promote cancer progression, whereas the vast majority, known as "passenger" mutations, confer little or no advantage to tumor growth. The combination of driver and passenger mutations is collectively referred to as the mutated gene set (MGS) of a particular tumor. 4 The most commonly used approaches to delineate driver mutations within MGS are based on frequency, postulating that mutations which occur more often are the most probable to be involved in cancer progression. 5 A notable frequency-based systematic approach is the Genomic Identification of Significant Targets in Cancer (GISTIC) method, which identifies driver genes through isolating regions with copy number variants that occur at a statistically significant frequency within large sample sizes. 6 However, a major limitation of frequency-based analyses is that they fail to detect driver mutations that occur at low rates (ie, "long tail mutations"), and these changes potentially may comprise the majority of driver mutations. Another disadvantage of the GISTIC approach is that, because copy number variant regions are characteristically large and contain several genes, GISTIC often cannot reliably discriminate between driver and passenger mutations.
In recent years, groups have been steadily innovating novel, systematic methods of identifying driver mutations with better precision by analyzing genomic data sets with network-assisted approaches, and the networks used include associated functional changes, 7 molecular pathways, 8 and disease phenotypic similarity. 9 These strategies have led to an unprecedented rate in the identification of functionally relevant driver genes in melanoma. In a noteworthy study in 2012, Hodis et al used a permutation-based approach to delineate driver mutations in melanoma, which controlled for passenger mutations with gene-specific basal mutational rates. 10 Those investigators identified 262 driver mutations in 21 genes, including 6 novel melanoma genes harboring driver mutations (protein phosphatase 6 primary and/or metastatic melanomas from 331 patients. 11 That study analyzed the cancer genomes with the aforementioned permutation-based approach and MutSigCV software (Broad Institute, Cambridge, Mass), which controls mutation burden for patient-specific mutation frequency while also adjusting for messenger RNA (mRNA) expression and gene-specific DNA replication time. 12 The combination of these 2 novel analytic approaches applied to the large tumor cohort delineated 48 core melanoma genes, presumably including the most significant driver genes. 11 Since that study, several other notable melanoma genomic studies have offered new insights into driver mutations. [13] [14] [15] [16] In addition, currently, there are various molecular testing platforms available to identify somatic mutations is melanoma. Because the identification of somatic mutations can play a critical role in prognostication and targeted therapy approaches, it is now essential to optimize molecular testing platforms for detection. DNA sequencing platforms are most commonly used, including the conventional single-gene analysis (eg, Sanger sequencing, pyrosequencing) and newer broader platforms (eg, wholegenome, targeted-exome, and hot-spot mutation panels). 17 Single-gene testing is effective in identifying isolated mutations like the B-raf proto-oncogene serine/ threonine kinase (BRAF) valine-to-glutamic acid substitution at codon 600 (V600E), or validating the findings from broader platforms. Although more information can be gained from available, broader next-generation sequencing platforms, limitations of institutions and costs of outsourcing are challenging realities. 17 Perhaps routine next-generation sequencing for melanoma may be supported by health care plans if data conclusively demonstrate improved patient outcomes through a role in guidance of targeted therapies. In this review, we discuss the most significant somatic driver mutations within the subtypes of primary melanoma, with emphasis on novel insights from the recent literature and treatment implications.
NONACRAL CUTANEOUS MELANOMA
Nonacral cutaneous melanomas (non-ACMs) are classified into 3 major clinicohistopathologic subtypes: superficial spreading melanoma (SSM), nodular melanoma (NM), and lentigo maligna melanoma (LMM). SSM is the most common variant and represents approximately 65% of all primary melanomas. 18 SSM classically occurs in regions of intermediate sun exposure and is characterized by a prominent radial growth phase before a vertical growth phase. 19 NM represents up to 15% of melanomas and is characterized by rapid vertical growth in the absence of horizontal growth. 19 LMM comprises an estimated 4% to 15% of primary melanomas, and it presents in sun-damaged regions, classically on the head and neck, in elderly patients. 20 LMM is characterized by a slow, prolonged, radial growth phase before vertical growth. Below, we review the driver mutations involved in non-ACM.
BRAF
The BRAF gene encodes for a serine/threonine protein kinase, which is critical in the regulation of the rat sarcoma/Raf kinase/mitogen-activated protein kinase kinase/ extracellular signal-regulated kinase (RAS/RAF/MEK/ ERK) signaling pathway (the mitogen-activated protein kinase [MAPK] pathway); this pathway is involved in many important cell functions, including proliferation, differentiation, and survival ( Fig. 1) . 21 BRAF mutations, which are identified in approximately 60% of melanomas, were first characterized in human malignancies in 2002. 22 The most common mutation (V600E) represents 80% of BRAF-mutant, primary melanomas and results in the constitutive activation of MEK and ERK signaling, driving cancer progression. 22 Other driver mutations in BRAF are valine-to-lysine (V600K) and valine-to-arginine (V600R) mutations, which comprise 20% and 7% of BRAF mutations, respectively. 23 It is worth noting that approximately 80% of benign nevi harbor BRAF V600E mutations; hence, BRAF mutations alone are not sufficient to drive tumorigenesis. 24 BRAF mutations are typically associated with melanomas identified in younger patients and from sites with intermittent sun exposure. 25 In 2010, targeted therapy aimed at BRAF mutations in patients with metastatic melanoma produced impressive results in preliminary trials, with partial or complete tumor regression in the majority of treated patients. 26 In a seminal, phase 3 clinical trial, compared with the traditional chemotherapeutic agent (dacarbazine), vemurafenib (the first US Food and Drug Administrationapproved BRAF V600E inhibitor) demonstrated marked improvements in overall survival (OS) (6-month survival rate, 84% vs 64%) and progression-free survival (PFS) (5.3 vs 1.6 months). 2 However, long-term follow-up studies reported that OS was limited to 16 months among those who received vemurafenib monotherapy. 27 Several mechanisms involved in resistance to BRAF inhibition in melanoma have been characterized. Tumor genomic profiling revealed that mutations in the downstream kinase MEK1 (MAP kinase kinase), which results in constitutive activation of ERK, confer therapeutic resistance. 28 Another mechanism of acquired resistance to BRAF inhibition is an activating mutation in neuroblastoma rat sarcoma viral oncogene homolog (NRAS), which drives the activation of CRAF (RAF proto-oncogene serine/threonine protein kinase), leading to the sustained upregulation of MEK and ERK signaling. 29 Another major resistance mechanism is the formation of splice variants of BRAF V600E that lack exons 4 through 8, which contain the RAS-binding domain. The p61 BRAF V600E variant leads to constitutive ERK signaling, which is resistant to RAF inhibition. 30 Also, hyperactivation of receptor tyrosine kinases, such as platelet-derived growth factor receptor b (PDFRb), insulin-like growth factor 1 receptor (IGF-1R), and erythropoietin-producing hepatocellular (EPH) receptors-leading to induction of the phosphoinositide 3-kinase (PI3K) pathway in patients who receive treatment with either BRAF or MEK inhibitors-has also been implicated in treatment resistance. 23, [31] [32] [33] [34] Another interesting resistance avenue recently characterized is the Figure 1 . Somatic mutations in genes involved in the mitogen-activated protein kinase (MAPK) and the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) pathways are well characterized drivers of melanoma. BRAF indicates B-raf proto-oncogene serine/threonine kinase; ERK1/2, extracellular signal-regulated kinases 1 and 2; KIT, KIT proto-oncogene receptor tyrosine kinase; MEK1/2, MAP kinase kinases 1 and 2; mTOR, mechanistic target of rapamycin; NRAS, neuroblastoma rat sarcoma viral oncogene homolog; PTEN, phosphatase and tensin homolog. overexpression of the epidermal growth factor receptor (EGFR) through negative feedback in patients who receive treatment with BRAF inhibitors (BRAFi) (note that EGFR is not normally expressed in nontreated melanomas). 35 Studies have demonstrated that EGFR inhibition leads to the restoration of sensitivity, indicating a possible future clinical strategy. 36 The current gold standard of targeted therapy in BRAF-mutant metastatic melanoma is a combination of BRAFi and MEK inhibitor (MEKi). In phase 1 and 2 clinical trials, a combination of the BRAFi dabrafenib with the MEKi trametinib led to marked improvements in the length of PFS (9.4 vs 5.8 months) and the rate of partial or complete responses (76% vs 54%) compared with dabrafenib monotherapy. 3 In a follow-up study to assess the endpoint of OS, the dabrafenib plus trametinib group had significantly improved OS rates of 74% at 1 year and 51% at 2 years compared with 68% and 42%, respectively, in the dabrafenib-only group. 37 In addition, in a randomized phase 3 trial, vemurafenib combined with the MEKi cobimetinib achieved significantly increased OS (22.3 months) compared with vemurafenib and placebo (17.4 months). 38 Currently, there is an ongoing clinical trial (clinicaltrials.gov identifier NCT02196181) evaluating the findings of preclinical studies suggesting that intermittent treatment with BRAFi/MEKi may delay resistance compared with continuous treatment. 39 It is noteworthy that BRAFi sensitivity is likely a unique feature of melanoma, because approximately 10% colorectal cancers harbor BRAF V600E mutations, and BRAF-mutant colorectal cancers have minimal response to BRAF or combination of BRAF/MEK inhibition. 40 Also, treatment of BRAF V600E melanomas with BRAFi in vitro resulted in increased melanoma antigen expression and increased sensitivity to antigen-specific T cells. 41 Conversely, MEK inhibition alone resulted in impaired T-cell function in vitro. 42 Combined BRAF and MEK inhibition led to increased programmed dealth-1 ligand (PD-L1) expression, demonstrating a immune-mediated mechanism of resistance to therapy. 43 These insights serve as the rationale for combing targeted therapies with immunomodulatory antibodies for melanoma. This synergistic strategy is currently being explored in an ongoing phase 3 trial of dabrafenib and trametinib followed by ipilimumab and nivolumab, and vice versa, in patients with advanced melanoma (clinicaltrials.gov identifier NCT02224781). BRAF driver mutations remain among the most investigated therapeutic targets in cancer research, with at least 80 open studies currently being conducted in melanoma.
A complete review of the investigation trials targeting BRAF is beyond the scope of this review.
NRAS
The RAS family consists of G-regulatory proteins, which are essential regulators in normal cell growth and malignant transformation, through the MAPK and the PI3K pathways. The 3 principal RAS proto-oncogenes are NRAS, Harvey RAS viral oncogene homolog (HRAS), and Kirsten RAS viral oncogene homolog (KRAS). NRAS mutations at codons 12, 13, and 61 comprise the second most common driver mutations in melanoma (20%) and are associated with increased aggressiveness and poor survival. 23 Hotspot mutations in other RAS genes in melanoma are exceedingly rare; HRAS and KRAS mutations were identified in only 1% of samples from TCGA set, whereas 28% of samples from the same cohort harbored NRAS mutations.
11 NRAS mutations are typically identified in melanomas from nonsun-damaged skin regions and are associated with increased thickness in primary tumors, higher mitotic rates, and lower incidence of ulceration. 21, 44 NRAS mutations have also been characterized in congenital melanocytic nevi, hence they are insufficient to be sole drivers of melanoma. 45 It is noteworthy that NRAS mutations are detected almost universally in melanomas without BRAF mutations; however, as described previously, they play an important role in resistance to targeted therapy with BRAFi. 46 Targeted therapies aimed directly at RAS mutations remain elusive. Current strategies are primarily focused on downstream inhibition of the MAPK pathway. In an open-label, phase 2 clinical trial, the MEK1/2 inhibitor binimetinib demonstrated a 20% response rate in patients with NRAS-mutant melanoma. 47 On the basis of those findings, a randomized phase 3 trial investigating binimetinib versus dacarbazine for NRAS-mutant melanoma is underway (clinicaltrials.gov identifier NCT01763164). Interim results from the trial were presented at the 2016 annual meeting of the American Society of Clinical Oncology. Although modest, treatment with binimetinib demonstrated improvements over dacarbazine in a prespecified interim analysis of OS (hazard ratio, 0.81). 48 Studies are also exploring MEK inhibitors in combination approaches. Preclinical studies demonstrated that cyclin-dependent kinase 4 (CDK4) plays a key role in preventing apoptosis in NRAS-mutant melanomas after inhibition of the MAPK pathway. These findings served as the rationale for exploring the synergistic potential of cotargeting MEK and CDK4 in a clinical trial. 49 Currently, 2 ongoing clinical trials are investigating the combination of MEK and CDK4/6 inhibitors in NRAS-mutant melanomas: binimetinib plus LEE011 (clinicaltrials.gov identifier NCT01781572) and trametinib plus palbociclib (clinicaltrials.gov identifier NCT01781572). Preliminary results from the binimetinib plus LEE011 trial were promising, with a 33% response rate in the setting of a tolerable side-effect profile. 50 There are currently no approved treatment regimens aimed at specifically targeting NRAS-mutant melanoma; however, there are several other potentially promising therapeutic strategies being explored, including RAF-265, an inhibitor of BRAF and vascular endothelial growth factor; BI-69-A11, an inhibitor of nuclear factor-jB and protein kinase B (AKT); and XL888, an inhibitor of heat-shock protein-90 and modulator of CDK4 and AKT activity.
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MITF
Microphthalmia-associated transcription factor (MITF) is a basic helix-loop-helix/leucine zipper transcription factor required for early melanocyte development, and it serves as a "lineage survival oncogene" in melanoma. 52 Alternative promoters and splicing of the MITF gene generates many different isoforms, which are regulated in a tissue-dependent manner, 53 and the M-MITF isoform is critical to melanocyte development and tumorigenesis. 54 This variant is identified in greater than 80% of melanomas; and it is present, although heterogeneously, in all stages of melanoma progression. 54 MITF amplification is observed in 20% of metastatic melanomas and is associated with decreased 5-year survival. 52, 55 Several transcription factors have been implicated in MITF activation, including paired box 3 (PAX3), SRY-box 10 (SOX10), lymphoid enhancer binding factor 1/T-cell factor (LEF1/ TCF), cyclic adenosine monophosphate response element-binding protein (CREB), and tyrosine-protein kinase receptor 3 (TYRO3). 56 Important transcriptional targets of MITF include genes involved in cell-cycle regulation (CDK2, T-box 2 (TBX2), cyclin-dependent kinase inhibitor 1A (p21), and cyclin-dependent kinase inhibitor Hypoxia-inducible factor a (HIF1a) also reportedly is activated by MITF and is implicated in tumor survival and metastases. 57 With regard to signaling cascades, MITF has been characterized as a required downstream target in melanoma growth mediated by the b-catenin pathway. 58 The role of MITF in the MAPK pathway is complex and has been steadily evolving in the recent literature.
Several major studies have confirmed that ERK phosphorylates MITF downstream of the receptor tyrosine kinase KIT. 59, 60 Although this phosphorylation induces activation, it also targets it for degradation through the ubiquitin-proteosome pathway. 61 Hence, the role of ERK-mediated phosphorylation of MITF in melanoma development remains uncertain. 54 However, with the use of zebrafish models, it has been reported that MITF is critical to the development of BRAF V600E-driven melanoma in vivo. 62 In addition, BRAF V600E has been characterized as closely regulating MITF expression. BRAF V600E can both induce MITF through the transcription factor BRN2 and down-regulate it by targeting MITF for degradation through ERK-mediated phosphorylation. 61 MITF has also been implicated in resistance to BRAFi/ MEKi. The antiapoptotic gene BCL2A1 is amplified in 30% of melanomas and is essential for melanoma growth. 63 MITF directly regulates BCL2-related protein A1 (BCL2A1) activation, and BCL2A1 over-expression abrogates BRAFi/MEKi-mediated apoptosis. 63 This elucidates how MITF confers resistance to BRAF/MEK inhibitors, particularly in the early stages of treatment, during which the majority of patients have an upregulation of MITF levels. 64 With respect to therapeutic strategies, to date, direct inhibition of MITF has not been plausible; however, the targeting of MITF-mediated pathways is currently being investigated. One such strategy is the use of histone deacetylase (HDAC) inhibitors, which have the ability to down-regulate MITF expression in vitro and in vivo. 65 There is currently an ongoing phase 2 trial exploring the treatment of resistant, metastatic melanoma with panobinostat (an HDAC inhibitor) and decitabine combined with chemotherapy (clinicaltrials.gov identifier NCT00925132).
Phosphatase and Tensin Homolog
Phosphatase and tensin homolog (PTEN) is a well characterized tumor-suppressor gene that encodes for the PTEN protein, a phosphatidyl-inositol-3,4,5-triphosphate 3-phosphatase and key regulator of the PI3K signaling pathway. Somatic PTEN alterations were identified in 14% of specimens in the TCGA melanoma cohort, consisting of both mutations (8%) and focal deletions (6%).
11 However, this frequency may significantly underestimate the incidence of PTEN mutations, because studies have suggested that PTEN mutations are more prevalent in invasive and metastatic melanomas than in early tumors. 66, 67 This is also supported by reports that PTEN loss was consistently demonstrated in approximately 30% of primary tumors, with even higher frequencies observed in melanoma cell lines. 32 PTEN mutations frequently coexist with BRAF mutations, but not with NRAS, which can independently activate the PI3K cascade. 68 It is likely that somatic alterations in other factors also involved in the activation the PI3K pathway may contribute to tumor progression, such as the PTEN-regulating protein
Phosphatidylinositol-3,4,5-trisphosphate RAC exchanger 2 (PREX2) mutations were identified in 27% of the TCGA melanoma cohort, which is a higher frequency than the 14% reported in a 2012 cohort. It has been demonstrated that ectopic expression of mutant PREX2 accelerates tumor formation of immortalized human melanocytes in vivo. 11, 69 In addition, loss of PTEN reportedly is an important factor in melanoma predisposition among individuals who harbor variants of the melanocortin-1 receptor (MC1R) gene. 55 Recent studies support the finding that loss of PTEN plays a key role in resistance to molecular and immune checkpoint inhibition. [70] [71] [72] In 2015, Peng et al demonstrated that silencing PTEN in melanoma cell lines resulted in a decreased ability of T cells to kill tumors. 70 In vivo, adoptively transferred T cells had a reduced ability to kill xenograft melanoma tumors with silenced PTEN expression compared with tumors that expressed PTEN. 70 In immunohistochemical analyses of a cohort of patients with metastatic melanoma who received treatment anti-programmed death-1 (anti-PD-1) antibodies (nivolumab or pembrolizumab), tumors that expressed PTEN underwent a greater reduction in size than tumors that did not express PTEN. Furthermore, attempts to culture tumor-infiltrating lymphocytes from melanoma tumors failed more in melanomas that were missing PTEN (26%) than those with PTEN present (11%). 70 On the basis of prior evidence that the PI3Kb isoform can activate the PI3K pathway in setting off PTEN loss, the authors investigated whether a PI3Kb-selective smallmolecule inhibitor (GSK2636771) can sensitize melanoma tumors to immunotherapy. 70, 73 In a murine model, the combination of the PI3Kbselective inhibitor and an immune checkpoint inhibitor (anti-PD-1 or anti-CTLA-4) resulted in greater tumor reduction in BRAF-mutant and PTEN-null melanomas than an immune checkpoint inhibitor alone. 70 Hence, these findings support the further exploration of PI3K inhibition in melanoma, and several early phase trials are currently underway investigating the efficacy of targeting PI3K (clinicaltrials.gov identifiers NCT02452294, NCT02159066, and NCT02961283).
Telomerase Reverse Transcriptase
The telomerase reverse transcriptase (TERT) gene encodes for a catalytic subunit of the holoenzyme telomerase. Telomerase is an enzyme essential for sustaining telomere length and chromosomal stability. Reactivation of the TERT gene enables cells to overcome replication-induced senescence, a critical step in tumor initiation; this is validated by the aberrant expression of TERT observed in 90% of aggressive malignancies. 74 Two large, independent genomic studies of melanoma reported recurrent mutations in the TERT promoter, which led to the generation of new binding motifs for the transcription factors E-26 (ETS) and ternary complex factors (TCFs). It was recently observed that these motifs facilitate binding of the critical transcription factor, GA-binding protein (GABP), leading to activation of TERT. [74] [75] [76] These mutations reportedly led to a 2-fold to 4-fold increase in the transcription of TERT. 75 The 2 recurrent mutations, located within 100 base pairs of the TERT transcriptional start site, were cysteine-to-threonine mutations at codon 228 (C228T) and codon 250 (C250T), consistent with an ultraviolet signature (C>T or CC>TT), thus implicating a role for ultraviolet induction. 75, 76 These mutations were identified in sporadic primary melanomas (33%), metastatic melanomas (85%), and melanoma cell lines (76%). 76 TERT promoter mutations are associated with BRAF and NRAS mutations and act as an independent factor of poor prognosis in non-ACM. 77 Clinical trials are ongoing or recently completed for imetelstat/ GRN163L, a telomerase antagonist, in other solid tumors and hematologic malignancies. If the results are promising, then these investigations could have implications for the development of new molecularly targeted therapies for melanoma and selecting patients based on somatic TERT promoter mutations or on telomere length in tumor cells.
RAC1
RAC1 encodes for an RHO GTPase (from the Ras superfamily of 20-kD to 30-kD guanosine-5 0 -triphosphate [GTP]-binding proteins) that plays a key role in cellular cytoskeleton organization and motility. Specifically, RAC proteins induce the development of membrane ruffles and lamellipodia through the regulation of actin polymerization; and dysregulation of RAC1 leads to cell proliferation and suppression of antitumor immune responses. 78 Recent exome sequencing studies identified a recurrent proline-to-serine mutation at codon 29 (P29S) of RAC1 in the conserved switch domain in melanoma cohorts. 79 This hotspot mutation was identified in 5% to 9% of melanomas and was the third most frequent driver mutation in sun-exposed melanomas after BRAF and NRAS.
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The P29S substitution is induced by a C>T transition, consistent with an ultraviolet-signature mutation. 79 This mutation leads to a fast-cycling GTPase, resulting in a GTP-bound state that accelerates cell proliferation. 78 Melanomas harboring RAC1 P29S mutations are associated with increased tumor thickness, increased mitotic rate, ulceration, and accompanying lymph node metastases at the time of diagnosis. 80 With regard to treatment, in vitro studies demonstrated that the RAC1 P29S mutation confers tumor resistance to RAFi and MEKi treatment and results in sustained activation of MAPK in the presence of inhibitors. In vivo, the mutation also led to a decreased RAFi effect on tumor growth. 81 It is noteworthy that Vu et al recently reported the up-regulation of PD-L1 expression by the RAC3 P29S mutation in melanoma cell lines. Those authors also observed significantly increased PD-L1 expression in patients who had RAC1 P29S mutations compared with wild-type RAC melanoma samples from the TCGA cohort. 78 These findings support the possibility that the RAC1 P29S mutation may drive tumor progression through suppression of the antitumor immune response, and they offer valuable insight into the potential benefit of anti-PD-1 or anti-PD-L1 antibodies for the treatment of patients who harbor this mutation.
Ribosomal Protein S27
The 5 0 -untranslated (UTR) region, which begins at the start site of mRNA transcription and extends to the base preceding the start codon (AUG), is involved in translational regulation. In the recent literature, mutations in this region have been increasingly characterized as drivers in cancer. One such important gene in melanoma, which harbors a hotspot, somatic 5 0 -UTR mutation, is ribosomal protein S27 (RPS27), In 2014, a systematic analysis of exome sequencing data from a cohort of 489 melanomas revealed recurrent mutations in the 5 0 -UTR of RPS27 in approximately 10% of melanomas. 82 This ranked RPS27 as the fourth most common gene with recurrent mutations in melanoma after TERT, BRAF, and NRAS. The RPS27 mutation results in a cysteine-to-threonine transition at the translational start site, which is part of the 5 0 -terminal oligopyrimidine tract (5 0 -TOP), a key motif involved in translation regulation in ribosomal proteins. 82 The mutation leads to lengthening the stretch of pyrimidine bases in 5 0 -TOP by 1 base (CTTTCC to CTTTTCC), conferring oncogenic properties. It has been hypothesized that the mutation leads to induction of the mTOR (mechanistic target of rapamycin) pathway, because growth was selectively inhibited by rapamycin. 82, 83 OTHER MUTATIONS In addition to the aforementioned driver mutations, other noteworthy alterations are implicated in non-ACMs. Tumor protein 53 (TP53) mutations are prevalent in approximately 20% of melanomas, which, although it is a comparatively lower frequency than in other malignancies, is nevertheless significant. 10, 55 The role of the p53 pathway in melanoma is further supported by the characterization of alterations in p53 regulators driving melanoma. Mouse double minute 2 (MDM2) and MDM4 are potent, negative regulators of p53 through promoting ubiquitin-dependent degradation. 84 Recently, it was demonstrated that both overexpression of MDM2 and amplification of MDM4 independently drive melanoma tumorigenesis; MDM4 is up-regulated in approximately 65% of melanomas. 85, 86 Early preclinical work suggests that p53 rescue through the use of MDM antagonists may be a viable clinical option. 87 AMG 232, a potent and selective small-molecule inhibitor of MDM2, is being investigated in combination with dabrafenib and trametinib in a phase 1b/2a study of patients with advanced melanoma (clinicaltrials.gov identifier NCT02110355).
In addition, cyclin-dependent kinase inhibitor 2A (CDKN2A), which encodes for p16INK4A (a CDK4/ CDK6 inhibitor that restricts cells from proceeding past the G1 checkpoint), is mutated in approximately 30% to 40% of families with melanoma. 88, 89 Sequencing for the 5 0 -UTR of the CDKN2A gene revealed a mutation (G>T) 34 base pairs upstream of the start codon, which gives rise to a novel AUG translation initiation site, resulting in decreased mRNA translation (compared with wild type) and promoting tumorigenesis. 89 In addition to being mutated in dysplastic nevus syndrome (B-K mole syndrome), a form of familial melanoma, CDKN2A/ p16INK4A forms a functional unit with CDK4, cyclin D1, and retinoblastoma, which is altered in 90% to 100% of melanomas. 90, 91 Genetic aberrations in CDKN2A have also been associated with poorer OS and PFS in patients who received dual BRAFi/MEKi treatment. 92 
DESMOPLASTIC MELANOMA
Desmoplastic melanoma (DM) is a variant of primary melanoma with distinct clinical and histopathologic features. DM often appears amelanotic with a scar-like appearance and is characterized histologically by spindleshaped, malignant melanocytes and abundant The Christie NHS Foundation Trust desmoplastic stroma. 93 DM comprises approximately 4% of primary melanomas, occurring more frequently in the head and neck region, and is more prevalent in elderly patients. 16, 94 DM is associated with a higher incidence of local recurrence and a lower incidence of metastasis to regional lymph nodes.
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NF1
Neurofibromin 1 (NF1) is a negative regulator of RAS through increasing RAS GTPase activity, leading to the conversion of RAS-GTP to the inactive RAS-guanosine diphosphate. Hence, NF1 inactivation results in the constitutive activation of the MAPK and PI3K pathways. NF1 is the third most common driver mutation in melanoma and has been reported in approximately 14% of melanomas. 23 In the TCGA cohort, 86% of melanomas had mutations in either BRAF, NRAS, or NF1.
11 In a recent whole-exome sequencing study of 213 melanomas, inactivating NF1 mutations were identified in 13% of the cohort and in 48% of wild-type BRAF and NRAS melanomas.
14 NF1 mutations were associated with sun-exposed melanomas and elderly patients and reportedly coexisted with mutations of other RASopathy genes, especially RAS p21 protein activator 2 (RASA2).
14 Of note, in this cohort, inactivation of NF1 did not predict response to MEKi or ERKi treatment. Recent literature also supports the finding that NF1 mutations may be distinct genetic drivers of DM. Until recently, little was known about genetic alterations involved in DM. In a pioneering study by Shain et al in 2015, exome sequencing of 20 DMs revealed that, of all tumor-suppressor candidates, NF1 had the highest burden of loss-of-function (LOF) mutations when the analysis was controlled for the expected loss-of-function burden calculated from permuted data. 16 Because most NF1 mutations result in a truncated or absent protein, another group performed the largest immunohistochemistry study to date of NF1 loss in DM, involving 78 DM samples, and observed that NF1 loss was more common in DM compared with other melanoma subtypes (69% vs 54%; P 5 .02). 95 ACM AND MUCOSAL MELANOMA ALM is rare subtype of primary melanoma that presents on the palms, soles, and subungual region, and it accounts for less than 2% of primary melanomas. 96 ALM is the most common primary melanoma in African Americans and Asians. 97 It is associated with a poor prognosis because of aggressive behavior and delayed diagnosis. 97 Mucosal melanoma is another rare subtype that comprises approximately 1.3% of primary melanomas and is also associated with a poor prognosis because of advanced stage at diagnosis.
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KIT KIT (KIT proto-oncogene receptor tyrosine kinase) encodes for a transmembrane receptor tyrosine kinase that binds the ligand stem cell factor, leading to dimerization, autophosphorylation, and activation of the intracellular kinase domain. Somatic mutations in KIT result in induction of both the MAPK and the PI3K pathways. Approximately 70% of KIT mutations identified in melanoma are localized to exon 11, most often a codon 576 lysine-toproline mutation (L576P), and to the kinase domain of exon 13, most often a codon 642 methionine-to-glutamic acid mutation (K642E); these alterations lead to constitutive activation of kinase activity. 55 Of note, mutations in KIT are characteristically mutually exclusive of BRAF and NRAS mutations. 99 Mutations in KIT are identified in 3% of all melanomas and are most common in those derived from acral, mucosal, and chronically sundamaged surfaces. 100 Comparative genomic hybridization data indicated that KIT mutations and/or copy numbers increased in 39% of mucosal melanomas, 36% of acral melanomas, and 28% of melanomas on chronically sundamaged skin. However, none were identified in melanomas from skin without chronic sun damage. 100 Clinical efficacy in treating melanomas that harbor KIT mutations has been evaluated with several kinase inhibitors, including imatinib, [101] [102] [103] dasatinib, 104 and sorafenib 105 However, most patients eventually experience disease progression. This may be partially attributable to the frequent presence of brain and central nervous system metastases in advanced melanoma, because smallmolecule kinase inhibitors have limited penetration in these regions. 99, 106 Nilotinib is a kinase inhibitor with greater potency than imatinib that targets a range of KIT mutations, including those in exons 9, 11, and 13. 107 In a phase 2 clinical trial, nilotinib demonstrated disease control in 27% of patients with advanced melanoma who were previously either refractory or intolerant to a KIT inhibitor. 99 Currently, a clinical trial (clinicaltrials.gov identifier NCT01738139) is recruiting patients who have advanced malignancies harboring somatic KIT mutations to study combination treatment with imatinib and the immunomodulatory agent ipilimumab. There are numerous additional investigational studies exploring KIT as a therapeutic target in melanoma (Table 1) ; however, a complete discussion of them is beyond the scope of this review.
Cyclin D1
The cyclin D1 (CCND1) encodes for the major cell cycle control protein cyclin D1. Cyclin D1 controls cell proliferation through bind and stimulating CDK4 and CDK6, resulting in phosphorylation of the retinoblastoma protein and subsequent cell cycle entry.
108 CCND1 is amplified in approximately 44% of ALM and 6% of SSM, implicating its role as a significant driver predominantly ALM. 109 Furthermore, amplification of CCND1 has been found to be involved in the development resistance to BRAF inhibitors in BRAF V600E melanomas. 108 UVEAL MELANOMA Uveal melanoma is a subtype that is the most common primary malignancy of the eye. It accounts for approximately 5% of primary melanomas and can originate from any region in the uveal tract, including the iris, ciliary body, and choroid. 110 The risk factors for uveal melanoma include fair skin, blue eyes, blonde or red hair, and the presence of nevi. 110 Unlike other primary melanomas, uveal melanoma predominantly metastasizes through hematogenous spread, and the most common sites of involvement are liver, lung, and bone. 110 
GNAQ/GNA11
The genes G protein subunit aQ (GNAQ) and G protein subunit a11 (GNA11) encode for Ga subunits of Gregulatory proteins of the RAS family, which are activated by guanosine-5 0 -triphosphate (GTP) and involved in many signaling pathways, including the MAPK and the PI3K pathways. Drivers mutations in GNAQ and GNA11 are involved the pathogenesis of uveal melanoma. 111, 112 GNAQ mutations are identified in approximately 33% of uveal melanomas and 1.4% of cutaneous melanomas, whereas GNA11 mutations are identified in approximately 39% of uveal melanomas and 1.3% of cutaneous melanomas. 113 However, clinical trial data suggest that up to 96% of uveal melanomas may harbor either GNAQ or GNA11 mutations, implicating a role of these mutations in the early development of nearly all uveal melanomas.
113
GNA11 mutations are more strongly associated with metastatic uveal melanoma than GNAQ. 55 Approximately 90% of GNAQ and GNA11 mutations occur at Q209. 113 It is noteworthy that these mutations are also mutually exclusive. 113 Based on promising results from in vitro MEK inhibition, a phase 2 randomized, multicenter clinical trial evaluating the MEK inhibitor selumetinib versus chemotherapy was performed in patients with metastatic uveal melanoma, and it revealed a significantly improved median PFS in the selumetinib group (16.1 weeks) over dacarbazine (7 weeks) . 114 Preclinical data supported findings that GNAQ induces uveal melanoma progression through protein kinase C-mediated activation of the MAPK and the nuclear factor jB pathways. 115 This is the rationale for a current phase 1 investigation of LXS196, an oral protein kinase C inhibitor, in patients with metastatic uveal melanoma (clinicaltrials.gov identifier NCT02601378).
CONCLUSION
In recent years, there has been an unprecedented growth in knowledge of the genomic and mutational landscape of melanoma. Several pioneering studies have contributed to the precise delineation of important driver mutations from a challenging background of passenger mutations. There have also been pertinent attempts aimed at classifying functionally relevant genomic alterations. For example, Vogelstein and colleagues proposed the "20 of 20 rule", which states that a driver gene can be designated as an oncogene if at least 20% of its mutations are missense mutations or as a tumor-suppressor gene if at least 20% of its mutations result in inactivation. 116 Such designations are helpful as we attempt to assign clinical value to mutations for the purposes of developing novel diagnostic and treatment strategies. We now know that a subset of somatic genetic mutations, in addition to playing a role in tumor formation and progression, is essential to the mechanisms involved in resistance to therapy. Hence, as we embark on the era of precision medicine, it becomes exceedingly important to understand the relevance of genomic perturbations to all facets of an individual's disease and management.
Although we have made remarkable progress in characterizing driver mutations in melanoma, there remain many more to be discovered and much more to learn of those we have identified. One specific dilemma is obtaining large enough cohorts to power the detection of rare mutations, which potentially may have the greatest clinical significance. This is particularly a challenge with noncutaneous melanomas and less common cutaneous subtypes, which are consistently underpowered in data sets. Another area that warrants further exploration is the effect of mutations in the noncoding genome. In recent years, there have been reports of several important driver mutations in the 5 0 -UTR and promoter regions, which modulate transcription factor binding sites or generate oncogenic transcript isoforms; in addition, it has been demonstrated that somatic mutations in the 3 0 -UTR disrupt microRNA binding sites essential to downstream pathway regulation. 88 Hence, there are limitations to whole-exome sequencing that need to be addressed to better illustrate the somatic mutational landscape of melanoma. The rapid advancement in genetic technology is promising, along with the evolving approaches in comprehensive and integrated data set analysis. These innovations will bring us closer to better outcomes for patients with melanoma.
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